Lipigon Q3 2024 - First Patient Recruited

Redeye comments on Lipigon’s third quarter report 2024. The same day as the report was released, the company communicated the enrolment of the first patient in the ongoing phase II study of Lipisense.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/